The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Integrative Clinical Genomics of Advanced Prostate Cancer
Open accessAbstract
Toward development of a precision medicine framework for metastatic, castration-resistant prostate cancer (mCRPC), we established a multi-institutional clinical sequencing infrastructure to conduct prospective whole-exome and transcriptome sequencing of bone or soft tissue tumor biopsies from a cohort of 150 mCRPC affected individuals. Aberrations of AR, ETS genes, TP53, and PTEN were frequent (40%-60% of cases), with TP53 and AR alterations enriched in mCRPC compared to primary prostate cancer. We identified new genomic alterations in PIK3CA/B, R-spondin, BRAF/RAF1, APC, β-catenin, and ZBTB16/PLZF. Moreover, aberrations of BRCA2, BRCA1, and ATM were observed at substantially higher frequencies (19.3% overall) compared to those in primary prostate cancers. 89% of affected individuals harbored a clinically actionable aberration, including 62.7% with aberrations in AR, 65% in other cancer-related genes, and 8% with actionable pathogenic germline alterations. This cohort study provides clinically actionable information that could impact treatment decisions for these affected individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The androgen receptor (AR) is a critical driver of prostate cancer (PCa).”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [1]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455 · cited 1×
“The consortium utilized two sequencing and analysis centers, one centralized digital pathology review center, and one centralized data visualization portal (Cerami et al., 2012; Gao et al., 2013; Robinson et al., 2011; Thorvaldsdóttir et al., 2013).”
Self-citationRobinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390 · cited 3×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160
Self-citationTrapnell, C., Roberts, A., Goff, L. A., Pertea, G. M., Kim, D., Kelley, D. R., Pimentel, H., Salzberg, S. L., Rinn, J. L., & Pachter, L. S. (2012) · Nature Protocols · doi:10.1038/nprot.2012.016 · Cited by 12,145
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“…analysis reveals that the majority of affected individuals with metastatic castration-resistant prostate cancer harbor clinically actionable molecular alterations, highlighting the need for genetic counseling to inform precision medicine in affected individuals with advanced prostate cancer.”
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D. B., Sougnez, C. L., Gabriel, S., Meyerson, M. M., Lander, E. S., & Getz, G. A. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,965 · cited 2×
“Somatic mutation analysis was performed as described previously (Cibulskis et al., 2013; Van Allen et al., 2014c) and reviewed with Integrated Genomics Viewer (IGV) (Robinson et al., 2011).”
Self-citationIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586 · cited 1×
“…on the PI3K pathway, PIK3CB-specific inhibitors may have utility in affected individuals with mutation, amplification, and/or fusion of this gene (Schwartz et al., 2015); multiple affected individuals who achieved durable (>1 year) responses to PIK3CB-specificin inhibition harbored activating…”
Self-citationAbiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Self-citationRecurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846 · cited 1×
“Among chimeric fusion transcripts identified, recurrent ETS fusions (Tomlins et al., 2005) were observed in 84 cases (56%), of which the majority were fused to ERG and others to FLI1, ETV4, and ETV5 (Figure 3B).”
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,007
Rauluševičiūtė, I., Drabløs, F., & Rye, M. B. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0657-6 · Cited by 129
Kohli, M., Tan, W. W., Zheng, T., Wang, A., Montesinos, C., Wong, C., Du, P., Jia, S., Yadav, S., Horvath, L. G., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102728 · Cited by 137
A modular master regulator landscape controls cancer transcriptional identity
Paull, E., Aytés, À., Jones, S. J., Subramaniam, P. S., Giorgi, F. M., Douglass, E. F., Tagore, S., Chu, B., Vasciaveo, A., Zheng, S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.045 · Cited by 137
Resistance to second-generation androgen receptor antagonists in prostate cancer
Schmidt, K. T., Huitema, A. D. R., Chau, C. H., & Figg, W. D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00438-4 · Cited by 146
Crona, D. J., & Whang, Y. E. (2017) · Cancers · doi:10.3390/cancers9060067 · Cited by 143
Zhang, D., Hu, Q., Liu, X., Ji, Y., Chao, H., Liu, Y., Tracz, A., Kirk, J. S., Buonamici, S., Zhu, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15815-7 · Cited by 135
Mahajan, K. N., Malla, P., Lawrence, H. R., Chen, Z., Kumar‐Sinha, C., Malik, R., Shukla, S. K., Kim, J., Coppola, D., Lawrence, N. J., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.05.003 · Cited by 139
Mazzu, Y. Z., Armenia, J., Chakraborty, G., Yoshikawa, Y., Coggins, S. A., Nandakumar, S., Gerke, T. A., Pomerantz, M. M., Qiu, X., Zhao, H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4046 · Cited by 156
Self-citationChromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function
Feng, F. Y.-C., Bono, J. S. D., Rubin, M. A., & Knudsen, K. E. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.04.016 · Cited by 133
Self-citationLuo, J., Attard, G., Balk, S. P., Bevan, C. L., Burnstein, K. L., Cato, L., Cherkasov, A. R., Bono, J. S. D., Dong, Y., Gao, A. C., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.11.038 · Cited by 134
Self-citationChaudagar, K. K., Hieromnimon, H. M., Khurana, R., Labadie, B. W., Hirz, T., Mei, S., Hasan, R., Shafran, J. S., Kelley, A., Apostolov, E., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3350 · Cited by 137
Basourakos, S. P., Li, L., Aparicio, A. M., Corn, P. G., Kim, J., & Thompson, T. C. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666161214114948 · Cited by 136
The treatment landscape of metastatic prostate cancer
Yamada, Y., & Beltran, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.06.010 · Cited by 139
Self-citationTargeting DNA repair pathway in cancer: Mechanisms and clinical application
Wang, M., Chen, S., & Ao, D. (2021) · MedComm · doi:10.1002/mco2.103 · Cited by 140
Chen, W. S., Aggarwal, R. R., Zhang, L., Zhao, S. G., THOMAS, G. V., Beer, T. M., Quigley, D. A., Foye, A., Playdle, D., Huang, J., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.03.020 · Cited by 130
Self-citationActivation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer
Li, S., Fong, K.-W., Gritsina, G., Zhang, A., Zhao, J. C., Kim, J., Sharp, A., Yuan, W., Aversa, C., Yang, X. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2812 · Cited by 131
Self-citationGruber, J. J., Afghahi, A., Timms, K. M., DeWees, A., Gross, W., Aushev, V. N., Wu, H.-T., Balcioglu, M., Sethi, H., Scott, D., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00439-1 · Cited by 135
Exome Sequencing of African-American Prostate Cancer Reveals Loss-of-Function ERF Mutations
Huang, F. W., Mosquera, J. M., Garofalo, A., Oh, C., Baco, M. B., Amin‐Mansour, A., Rabasha, B., Bahl, S., Mullane, S. A., Robinson, B. D., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0960 · Cited by 136
Self-citationMolecular and cellular mechanisms of castration resistant prostate cancer (Review)
Huang, Y., Jiang, X., Liang, X., & Jiang, G. (2018) · Oncology Letters · doi:10.3892/ol.2018.8123 · Cited by 137
Tsujino, T., Takai, T., Hinohara, K., Gui, F., Tsutsumi, T., Bai, X. F., Miao, C., Feng, C., Gui, B., Sztupinszki, Z. M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35880-y · Cited by 137
The role of GATA2 in lethal prostate cancer aggressiveness
Rodríguez-Bravo, V., Carceles‐Cordon, M., Hoshida, Y., Cordon‐Cardo, C., Galsky, M. D., & Domenech, J. M. D. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.225 · Cited by 128
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
Gao, S., Chen, S., Han, D. G., Wang, Z., Li, M., Han, W., Besschetnova, A., Liu, M., Zhou, F., Barrett, D. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0681-7 · Cited by 132
Self-citationA New Old Target: Androgen Receptor Signaling and Advanced Prostate Cancer
Westaby, D., de la Maza, M. D. F., Paschalis, A., Jiménez‐Vacas, J. M., Welti, J. C., Bono, J. S. D., & Sharp, A. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052220-015912 · Cited by 133
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
Androgen receptor splice variants and prostate cancer: From bench to bedside
Wadosky, K. M., & Koochekpour, S. (2017) · Oncotarget · doi:10.18632/oncotarget.14537 · Cited by 135
Radium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 133
Self-citationPARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Min, A., & Im, S. (2020) · Cancers · doi:10.3390/cancers12020394 · Cited by 134
Böttcher, R., Kweldam, C. F., Livingstone, J. M., Lalonde, E., Yamaguchi, T. N., Huang, V., Yousif, F., Fraser, M. E., Bristow, R. G., van der Kwast, T., et al. (2018) · BMC Cancer · doi:10.1186/s12885-017-3976-z · Cited by 128
Hoang, D. T., Iczkowski, K. A., Kilari, D., See, W. A., & Nevalainen, M. T. (2016) · Oncotarget · doi:10.18632/oncotarget.12554 · Cited by 132
Shenoy, T., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx165 · Cited by 128
Self-citationBiological Evolution of Castration-resistant Prostate Cancer
Davies, A., Conteduca, V., Zoubeidi, A., & Beltran, H. (2019) · European Urology Focus · doi:10.1016/j.euf.2019.01.016 · Cited by 126
Self-citationATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer
Rafiei, S., Fitzpatrick, K., Liu, D., Cai, M.-Y., Elmarakeby, H., Park, J., Ricker, C. A., Kochupurakkal, B. S., Choudhury, A. D., Hahn, W. C., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3126 · Cited by 131
Self-citationMAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
de Leeuw, R., McNair, C. M., Schiewer, M. J., Neupane, N. P., Brand, L. J., Augello, M. A., Li, Z., Cheng, L. C., Yoshida, A., Courtney, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0410 · Cited by 126
Self-citationEpigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 131
Androgen action in prostate function and disease.
Banerjee, P. P., Banerjee, S., Brown, T. R., & Zirkin, B. R. (2018) · Europe PMC (PubMed Central) · Cited by 124
Barata, P. C., Agarwal, N., Nussenzveig, R. H., Gerendash, B., Jaeger, E., Hatton, W., Ledet, E. M., Lewis, B. E., Layton, J. L., Babiker, H. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001065 · Cited by 129
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Neeb, A., Herranz, N., Arce‐Gallego, S., Miranda, S., Buroni, L., Yuan, W., Athie, A., Casals, T., Carmichael, J. A., Rodrigues, D. N., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.10.029 · Cited by 127
Self-citationClinical variability and molecular heterogeneity in prostate cancer
Barbieri, C. E., & Shoag, J. E. (2016) · Asian Journal of Andrology · doi:10.4103/1008-682x.178852 · Cited by 124
Telomeres and telomerase in prostate cancer development and therapy
Graham, M. K., & Meeker, A. K. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.104 · Cited by 125
Lv, S., Ji, L., Chen, B., Liu, S., Lei, C., Liu, X., Qi, X., Wang, Y., Leung, E. L., Wang, H., et al. (2017) · Oncogene · doi:10.1038/s41388-017-0026-x · Cited by 128
Lawrence, M. G., Obinata, D., Sandhu, S. K., Selth, L. A., Wong, S. Q., Porter, L. H., Lister, N. L., Pook, D. W., Pezaro, C. J., Goode, D. L., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.06.020 · Cited by 123
Tyekucheva, S., Bowden, M., Bango, C., Giunchi, F., Huang, Y., Zhou, C. W., Bondi, A., Lis, R. T., Hemelrijck, M. V., Andrén, O., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00460-4 · Cited by 124
Self-citationMateo, J., Cheng, H. H., Beltran, H., Dolling, D. I., Xu, W., Pritchard, C. C., Mossop, H., Rescigno, P., Pérez-López, R., Sailer, V., et al. (2018) · European Urology · doi:10.1016/j.eururo.2018.01.010 · Cited by 124
Self-citationTagawa, S. T., Antonarakis, E. S., Gjyrezi, A., Galletti, G., Kim, S., Worroll, D., Stewart, J. A., Zaher, A., Szatrowski, T. P., Ballman, K. V., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0320 · Cited by 124
Self-citationSpratt, D. E., Alshalalfa, M., Fishbane, N., Weiner, A. B., Mehra, R., Mahal, B. A. V., Lehrer, J. M., Liu, Y., Zhao, S. G., Speers, C. W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1587 · Cited by 122
Self-citationFox, J. J., Gavane, S. C., Blanc-Autran, E., Nehmeh, S. A., Gönen, M., Beattie, B., Vargas, H. A., Schöder, H. M., Humm, J. L., Fine, S. W., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3588 · Cited by 121
Self-citationNSD2 is a conserved driver of metastatic prostate cancer progression
Aytés, À., Giacobbe, A., Mitrofanova, A., Ruggero, K., Cyrta, J., Arriaga, J. M., Palomero, L., Farran-Matas, S., Rubin, M. A., Shen, M. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07511-4 · Cited by 122
Self-citationLiquid Biopsy in Prostate Cancer Management—Current Challenges and Future Perspectives
Crocetto, F., Russo, G., Zazzo, E. D., Pisapia, P., Mirto, B. F., Palmieri, A., Pepe, F., Bellevicine, C., Russo, A., Civita, E. L., et al. (2022) · Cancers · doi:10.3390/cancers14133272 · Cited by 122
Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer
Ahmad, I., Mui, E. J., Galbraith, L. C. A., Patel, R., Tan, E. H., Salji, M. J., Rust, A. G., Repiščák, P., Hedley, A., Markert, E. K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601571113 · Cited by 121
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
Li, N., Xue, W., Yuan, H., Dong, B., Ding, Y., Liu, Y., Jiang, M., Kan, S., Sun, T., Ren, J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91144 · Cited by 119
Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and TherapiesPreprint
Puca, L., Vlachostergios, P. J., & Beltran, H. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030593 · Cited by 120
Self-citationCDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation
Rasool, R. U., Natesan, R., Deng, Q., Aras, S., Lal, P., Effron, S. S., Mitchell-Velasquez, E., Posimo, J. M., Carskadon, S. L., Baca, S. C., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0189 · Cited by 118
Self-citationNguyen, B., Mota, J. M., Nandakumar, S., Stopsack, K. H., Weg, E. S., Rathkopf, D. E., Morris, M. J., Scher, H. I., Kantoff, P. W., Gopalan, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.024 · Cited by 122
Self-citationGiri, V. N., & Beebe‐Dimmer, J. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.08.001 · Cited by 126
Emerging biomarkers in the diagnosis of prostate cancer
Filella, X., Fernández‐Galán, E., Fernández, R. M. S., & Foj, L. (2018) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s136026 · Cited by 117
Revisiting the role of Wnt/β-catenin signaling in prostate cancer
Schneider, J. A., & Logan, S. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.008 · Cited by 115
Dysregulation of spliceosome gene expression in advanced prostate cancer by RNA-binding protein PSF
Takayama, K., Suzuki, T., Fujimura, T., Yamada, Y., Takahashi, S., Homma, Y., Suzuki, Y., & Inoue, S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1706076114 · Cited by 114
Jolly, M. K., Kulkarni, P., Weninger, K., Orban, J. P., & Levine, H. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00050 · Cited by 116
A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers
Smith, B. A., Balanis, N. G., Nanjundiah, A., Sheu, K. M., Tsai, B. L., Zhang, Q., Park, J. W., Thompson, M. J., Huang, J., Witte, O. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.062 · Cited by 116
Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents
Salehi, B., Fokou, P. V. T., Yamthé, L. R. T., Tali, M. B. T., Adetunji, C. O., Rahavian, A., Mudau, F. N., Martorell, M., Setzer, W. N., Rodrigues, C. F., et al. (2019) · Nutrients · doi:10.3390/nu11071483 · Cited by 118
Zhao, D., Cai, L., Lü, X., Liang, X., Li, J., Chen, P., Ittmann, M., Shang, X., Jiang, S., Li, H., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1352 · Cited by 116
The Proteome of Prostate Cancer Bone Metastasis Reveals Heterogeneity with Prognostic Implications
Iglesias-Gato, D., Thysell, E., Tyanova, S., Crnalic, S., Santos, A., Lima, T. S., Geiger, T., Cox, J., Widmark, A., Bergh, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1229 · Cited by 106
Molecular Subtypes of Prostate Cancer
Arora, K., & Barbieri, C. E. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0707-9 · Cited by 119
Yuan, J., Kensler, K. H., Hu, Z., Zhang, Y., Zhang, T., Jiang, J., Xu, M., Pan, Y., Long, M., Montone, K. T., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1008641 · Cited by 116
BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
Messina, C. G. M., Cattrini, C., Soldato, D., Vallome, G., Caffo, O., Castro, E., Olmos, D., Boccardo, F., & Zanardi, E. (2020) · Journal of Oncology · doi:10.1155/2020/4986365 · Cited by 116
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression
Bolis, M., Bossi, D., Vallerga, A., Ceserani, V., Cavalli, M., Impellizzieri, D., Rito, L. D., Zoni, E., Mosole, S., Elia, A. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26840-5 · Cited by 124
Self-citationBarfeld, S. J., Urbanucci, A., Itkonen, H. M., Fazli, L., Hicks, J. L., Thiede, B., Rennie, P. S., Yegnasubramanian, S., Marzo, A. M. D., & Mills, I. G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.006 · Cited by 113
Nuclear receptors in cancer — uncovering new and evolving roles through genomic analysis
Dhiman, V. K., Bolt, M. J., & White, K. P. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.102 · Cited by 117
Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression
Chakraborty, G., Armenia, J., Mazzu, Y. Z., Nandakumar, S., Stopsack, K. H., Atiq, M. O., Komura, K., Jehane, L. E., Hirani, R., Chadalavada, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1570 · Cited by 116
Self-citationPD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 114
Ma, X., Guo, J., Liu, K., Chen, L., Liu, D., Dong, S., Xia, J., Long, Q., Yue, Y., Zhao, P., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01264-9 · Cited by 116
BRCA Mutations in Ovarian and Prostate Cancer: Bench to Bedside
Boussios, S., Rassy, E., Moschetta, M., Ghose, A., Adeleke, S. M., Sanchez, E., Sheriff, M., Chargari, C., & Pavlidis, N. A. (2022) · Cancers · doi:10.3390/cancers14163888 · Cited by 117
METTL1 promotes tumorigenesis through tRNA-derived fragment biogenesis in prostate cancer
García-Vílchez, R., Añazco-Guenkova, A. M., Dietmann, S., López, J., Morón-Calvente, V., D’Ambrosi, S., Nombela, P., Zamacola, K., Mendizabal, I., Garcia‐Longarte, S., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01809-8 · Cited by 118
Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 117
Self-citationSomatic CACNA1H Mutation As a Cause of Aldosterone-Producing Adenoma
Nanba, K., Blinder, A., Rege, J., Hattangady, N. G., Else, T., Liu, C., Tomlins, S. A., Vats, P., Kumar‐Sinha, C., Giordano, T. J., et al. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.14349 · Cited by 121
Self-citationWang, M., Chen, J., Lu, Y., Bawcom, A. R., Wu, J., Ou, J., Asara, J. M., Armstrong, A. J., Wang, Q., Li, L., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci166647 · Cited by 121
“(42) data sets but not in the Abida et al.”
A ZNRF3-dependent Wnt/β-catenin signaling gradient is required for adrenal homeostasisPreprint
Basham, K. J., Rodriguez, S., Turcu, A. F., Lerário, A. M., Logan, C. Y., Rysztak, M. R., Gómez-Sánchez, C. E., Breault, D. T., Koo, B., Clevers, H. C., et al. (2019) · Genes & Development · doi:10.1101/gad.317412.118 · Cited by 118
A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer
Bai, S., Cao, S., Jin, L., Kobelski, M. M., Schouest, B., Wang, X., Ungerleider, N., Baddoo, M., Zhang, W., Corey, E., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0768-8 · Cited by 119
Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management
Koo, K. M., Mainwaring, P. N., Tomlins, S. A., & Trau, M. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0178-2 · Cited by 109
Self-citationDNA copy number changes define spatial patterns of heterogeneity in colorectal cancer
Mamlouk, S., Childs, L. H., Aust, D. E., Heim, D., Melching, F., de Oliveira, C. M. M., Wolf, T. A., Durek, P., Schumacher, D., Bläker, H., et al. (2017) · Nature Communications · doi:10.1038/ncomms14093 · Cited by 114
Frizzled-8 integrates Wnt-11 and transforming growth factor-β signaling in prostate cancer
Murillo-Garzón, V., Gorroño‐Etxebarria, I., Åkerfelt, M., Puustinen, M. C., Sistonen, L., Nees, M., Carton, J., Waxman, J., & Kypta, R. M. (2018) · Nature Communications · doi:10.1038/s41467-018-04042-w · Cited by 114
Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment
Mansinho, A., Macedo, D., Fernandes, I., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-99286-0_7 · Cited by 113
Waddell, A. R., Huang, H., & Liao, D. (2021) · Cancers · doi:10.3390/cancers13122872 · Cited by 110
Liu, X., Grogan, T., Hieronymus, H., Hashimoto, T., Mottahedeh, J., Cheng, D., Zhang, L., Huang, K. Y., Stoyanova, T. I., Park, J. W., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.010 · Cited by 107
Self-citationTherapeutic Approaches Targeting MYC-Driven Prostate Cancer
Rebello, R. J., Pearson, R. B., Hannan, R. D., & Furic, L. (2017) · Genes · doi:10.3390/genes8020071 · Cited by 110
Goto, Y., Kurozumi, A., Arai, T., Nohata, N., Kojima, S., Okato, A., Kato, M., Yamazaki, K., Ishida, Y., Naya, Y., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.191 · Cited by 110
Lineage Plasticity in Cancer Progression and Treatment
Magnen, C. L., Shen, M. M., & Abate-Shen, C. T. (2017) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050224 · Cited by 105
The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis
Mei, W., Lin, X., Kapoor, A., Gu, Y. J., Zhao, K., & Tang, D. (2019) · Cancers · doi:10.3390/cancers11040434 · Cited by 110
Chatterjee, P., Schweizer, M. T., Lucas, J. M., Coleman, I., Nyquist, M. D., Frank, S. B., Tharakan, R., Mostaghel, E. A., Luo, J., Pritchard, C. C., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127613 · Cited by 107
Self-citationTOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup
Labbé, D. P., Sweeney, C. J., Brown, M. A., Galbo, P. M., Rosario, S. R., Wadosky, K. M., Ku, S., Sjöström, M., Alshalalfa, M., Erho, N., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0413 · Cited by 111
Self-citationSingle-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis
Lambros, M. B. K., Seed, G., Sumanasuriya, S., Gil, V., Crespo, M., Fontes, M. S., Chandler, R., Mehra, N., Fowler, G., Ebbs, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0862 · Cited by 108
Self-citationHistone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
Vatapalli, R. J., Sagar, V., Rodríguez, Y., Zhao, J. C., Unno, K., Pamarthy, S., Lysy, B., Anker, J. F., Han, H., Yoo, Y. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18013-7 · Cited by 111
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Michmerhuizen, A. R., Spratt, D. E., Pierce, L. J., & Speers, C. W. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00190-9 · Cited by 111
Long non-coding RNAs in genitourinary malignancies: a whole new world
Flippot, R., Beinse, G., Boilève, A., Vibert, J., & Malouf, G. G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0195-1 · Cited by 109
Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer
Lozano, R., Castro, E., Aragón, I. M., Cendón, Y., Cattrini, C., Lopez-Casas, P. P., & Olmos, D. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01114-x · Cited by 110
Li, N., Liu, Q., Han, Y., Pei, S., Cheng, B., Xu, J., Miao, X., Pan‐Hammarström, Q., Wang, H., Guo, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34871-9 · Cited by 112
“Immunostaining of TMA (adjacent normal tissues: 40; tumor sample: 100; Supplementary Table 1) were performed by Department of Pathology at the Daping Hospital, Army Medical University by using anti-ARID1A (Cell Signaling Technology; 12354 S, clone: D2A8U, 1:500), CD8 (Abcam; ab189926, clone: EPR10640(2), 1:200), CD15…”
Fan, L., Zhang, F., Xu, S., Cui, X., Hussain, A., Fazli, L., Gleave, M. E., Dong, X., & Qi, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802415115 · Cited by 107
Yuan, Y., Du, Y., Wang, L., & Liu, X. (2020) · Journal of Cancer · doi:10.7150/jca.42338 · Cited by 106
Qiao, Y., Choi, J. E., Tien, J. C.-Y., Simko, S. A., Rajendiran, T. M., Vo, J. N., Delekta, A. D., Wang, L., Xiao, L., Hodge, N., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00237-1 · Cited by 106
Self-citationBRCA Mutations in Prostate Cancer: Assessment, Implications and Treatment Considerations
Shah, S., Rachmat, R., Enyioma, S., Ghose, A., Revythis, A., & Boussios, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312628 · Cited by 113
Metadata
- Authors
- Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., Beltran, H., Abida, W., Bradley, R. K., Vinson, J., Cao, X., Vats, P., Kunju, L. P., Hussain, M., Feng, F. Y., Tomlins, S. A., Cooney, K. A., Smith, D. C., Brennan, C., Siddiqui, J., Mehra, R., Chen, Y., Rathkopf, D. E., Morris, M. J., Solomon, S. B., Durack, J. C., Reuter, V. E., Gopalan, A., Gao, J., Loda, M., Lis, R. T., Bowden, M., Balk, S. P., Gaviola, G., Sougnez, C., Gupta, M., Yu, E. Y., Mostaghel, E. A., Cheng, H. H., Mulcahy, H., True, L. D., Plymate, S. R., Dvinge, H., Ferraldeschi, R., Flohr, P., Miranda, S., Zafeiriou, Z., Tunariu, N., Mateo, J., Perez-Lopez, R., Demichelis, F., Robinson, B. D., Schiffman, M., Nanus, D. M., Tagawa, S. T., Sigaras, A., Eng, K. W., Elemento, O., Sboner, A., Heath, E. I., Scher, H. I., Pienta, K. J., Kantoff, P., de Bono, J. S., Rubin, M. A., Nelson, P. S., Garraway, L. A., Sawyers, C. L., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Memorial Sloan Kettering Cancer Center (US)
- NewYork–Presbyterian Hospital (US)
- University of Washington (US)
- Dana-Farber Cancer Institute (US)
- Royal Marsden NHS Foundation Trust (GB)
- Howard Hughes Medical Institute (US)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- University of Washington Medical Center (US)
- University of Trento (IT)
- Cornell University (US)
- Wayne State University (US)
- Johns Hopkins University (US)
- Corresponding author
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- ORCID
- Robinson, Dan
- Schultz, Nikolaus
- Mosquera, Juan-Miguel
- Montgomery, Bruce
- Taplin, Mary-Ellen
- Pritchard, Colin C.
- Attard, Gerhardt
- Beltran, Himisha
- Abida, Wassim
- Bradley, Robert K.
- Vinson, Jake
- Cao, Xuhong
- Vats, Pankaj
- Kunju, Lakshmi P.
- Hussain, Maha
- Feng, Felix Y.
- Tomlins, Scott A.
- Cooney, Kathleen A.
- Smith, David C.
- Brennan, Christine
- Siddiqui, Javed
- Mehra, Rohit
- Chen, Yu
- Rathkopf, Dana E.
- Morris, Michael J.
- Solomon, Stephen B.
- Durack, Jeremy C.
- Gopalan, Anuradha
- Gao, Jianjiong
- Loda, Massimo
- Lis, Rosina T.
- Bowden, Michaela
- Gupta, Manaswi
- Yu, Evan Y.
- Mostaghel, Elahe A.
- Cheng, Heather H.
- Mulcahy, Hyojeong
- True, Lawrence D.
- Plymate, Stephen R.
- Dvinge, Heidi
- Flohr, Penny
- Miranda, Susana
- Zafeiriou, Zafeiris
- Tunariu, Nina
- Demichelis, Francesca
- Robinson, Brian D.
- Schiffman, Marc
- Nanus, David M.
- Tagawa, Scott T.
- Sigaras, Alexandros
- Eng, Kenneth W.
- Elemento, Olivier
- Sboner, Andrea
- Heath, Elisabeth I.
- Scher, Howard I.
- Pienta, Kenneth J.
- Kantoff, Philip
- Rubin, Mark A.
- Nelson, Peter S.
- Garraway, Levi A.
- Sawyers, Charles L.
- Chinnaiyan, Arul M.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-05
- Volume
- 161
- Issue
- 5
- Pages
- 1215-1228
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4484602
- OpenAlex
- W1578291413
- Cited by
- 3,645
- References
- 64
- Citations by year
- 2026: 178 · 2025: 258 · 2024: 320 · 2023: 363 · 2022: 360 · 2021: 392 · 2020: 378 · 2019: 346 · 2018: 358 · 2017: 355 · 2016: 263 · 2015: 63
- FWCI
- 273.95
- Type
- journal article
- Language
- en
- Update notices
- erratum (2015-07-16)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Iris (University of Trento) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- Cancer Research UK (13239)
- National Institute for Health and Care Research (CL-2008-22-001)
- Prostate Cancer UK (CEO13_2-002, PG12-49)
- National Institutes of Health (DP2OD002750)
- Medical Research Council (MR/M003272/1)
- National Human Genome Research Institute (UM1HG006508)
- National Cancer Institute (P50 CA 90381, R01CA136578, L30 CA111031, K08CA188615, R21CA128352, U01CA111275, P50CA090381, R01CA131945, UO1CA111275, L30 CA103810, R01CA116337, R01CA129435, P50CA069568, K08CA115927, R01CA092629, R01CA155169, R01CA193910, R01CA085912, P30CA008748, P01CA163227, P50CA097186, P50CA186786, P50CA092629, P30CA006516, R01CA193837)
- National Institute of General Medical Sciences (T32GM007266, R01GM107427)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- metastatic castration-resistant prostate cancer, exome sequencing, transcriptome sequencing, actionable genomic alterations, androgen receptor alterations, ETS gene fusions, TP53, PTEN, R-spondin, APC, β-catenin, BRCA2, BRCA1, ATM, germline pathogenic variants, precision medicine
- MeSH terms
- Humans, Male, Mutation, Neoplasm Metastasis, Cohort Studies, Gene Expression Profiling, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
